GT Biopharma (GTBP) had the highest return between January 5, 2017 and April 14, 2017 by a US stock, returning 3,529,311.8%.
| ASSET | DATE | % RETURN |
|---|---|---|
GT Biopharma (GTBP) | 1/5/2017 - 4/14/2017 | 3,529,311.76% |
AquaBounty Technologies (AQB) | 1/5/2017 - 4/14/2017 | 136,011.11% |
Avalon GloboCare (ALBT) | 1/5/2017 - 4/14/2017 | 2,903% |
Ocean Power Technologies (OPTT) | 1/5/2017 - 4/14/2017 | 1,115.95% |
Duos Technologies (DUOT) | 1/5/2017 - 4/14/2017 | 427.7% |
Pulmatrix (PULM) | 1/5/2017 - 4/14/2017 | 413.56% |
TSS, Inc Common Stock (TSSI) | 1/5/2017 - 4/14/2017 | 324.75% |
Netcapital (NCPL) | 1/5/2017 - 4/14/2017 | 300% |
Pulse Biosciences (PLSE) | 1/5/2017 - 4/14/2017 | 268.04% |
Oncolytics Biotech (ONCY) | 1/5/2017 - 4/14/2017 | 266.24% |
Nutex Health (NUTX) | 1/5/2017 - 4/14/2017 | 257.14% |
Castellum (CTM) | 1/5/2017 - 4/14/2017 | 250% |
InMed Pharmaceuticals (INM) | 1/5/2017 - 4/14/2017 | 231.37% |
Aurinia Pharmaceuticals (AUPH) | 1/5/2017 - 4/14/2017 | 213.3% |
Galectin Therapeutics (GALT) | 1/5/2017 - 4/14/2017 | 200.95% |
OLB (OLB) | 1/5/2017 - 4/14/2017 | 200% |
Opus Genetics (IRD) | 1/5/2017 - 4/14/2017 | 189.81% |
Esperion Therapeutics (ESPR) | 1/5/2017 - 4/14/2017 | 180.99% |
Protalix Biotherapeutics (PLX) | 1/5/2017 - 4/14/2017 | 150% |
Ryvyl (RVYL) | 1/5/2017 - 4/14/2017 | 139.71% |
Viridian Therapeutics (VRDN) | 1/5/2017 - 4/14/2017 | 139.14% |
Quoin Pharmaceuticals Ltd DRC (QNRX) | 1/5/2017 - 4/14/2017 | 139.13% |
Akari Therapeutics (AKTX) | 1/5/2017 - 4/14/2017 | 122.5% |
Fennec Pharmaceuticals (FENC) | 1/5/2017 - 4/14/2017 | 116.43% |
Cenntro Electric (CENN) | 1/5/2017 - 4/14/2017 | 115.63% |
